ThermoDox heat-activated liposome: Phase III ongoing

For a sixth time, a DMC recommended continuation of the Phase III HEAT trial based on a review of data from 535 patients. The double-blind, sham-controlled, international trial is comparing 50 mg/m 2 IV ThermoDox plus radiofrequency ablation vs. radiofrequency ablation alone. The trial has enrolled about 587 of a planned 600 liver cancer patients. The DMC previously recommended continuation of the study after a review of the first 482 patients (see BioCentury, Feb. 21). ...